GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.

What Was Tested

Researchers studied Glucagon in this randomized controlled trial publication.

To examine the absorption of glucagon-like peptide (GLP)-1(7-36) amide from the buccal mucosa of type 2 diabetic patients.

Who Took Part

The study group was 2 patients.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

A total of 10 type 2 diabetic patients received a single tablet under fasting conditions and before a standard meal in this randomized placebo-controlled study.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

The patients were allocated by chance, so the Glucagon group and the comparison group should start out alike.

Neither the patients nor the staff measuring them knew who was on Glucagon, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Glucagon could be set against what happens without it.

In the crossover set-up each of the patients took both Glucagon and the comparison in turn, acting as their own control.

What Was Measured

PubMed files the paper under topics including Absorption, Administration, Buccal, Blood Glucose, Diabetes Mellitus, Type 2, Fasting, Glucagon and Glucagon-Like Peptide 1.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 9 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1997 (Diabetes care), a journal based in United States.

More context: the related Glucagon library page, all human trials.